All healthy volunteers completed the treatment phase and results are expected during the first quarter of 2015. BL-8040 is being developed along multiple tracks for the treatment of hematological malignancies and other hematological indications, with multiple clinical milestones expected in 2015.
http://ift.tt/1IlvuE2
http://ift.tt/1IlvuE2
No comments:
Post a Comment